Lannett Development Of Biosimilar Insulin Glargine Product Continues To Advance
- Wednesday, March 10, 2021, 7:14
- Business
- Add a comment
PHILADELPHIA, March 10, 2021 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced that it recently received feedback from the U.S. Food and Drug Administration (FDA) regarding biosimilar insulin glargine, a product the company is co-developing with its strategic alliance…
About the Author
adminasapcorp has written 41555 stories on this site.